Navigation Links
Novalar Receives FDA Approval for OraVerse(TM)
Date:5/12/2008

First approved dental anesthetic reversal agent

SAN DIEGO, May 12 /PRNewswire/ -- Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical company, announced today that the United States Food and Drug Administration (FDA) has granted marketing approval for OraVerse(TM) (phentolamine mesylate). OraVerse is the first pharmaceutical agent indicated for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from a local dental anesthetic. Novalar is establishing a specialty direct sales force to launch OraVerse in late 2008.

"The approval of OraVerse is the result of the outstanding efforts of our development team, our strong collaboration with the FDA and our focus and commitment to realizing the vision of our founder, Dr. Eckard Weber. This first-in-class therapeutic will provide dental professionals with a novel solution to enhance the overall experience for their patients," stated Donna Janson, President and Chief Executive Officer of Novalar.

Novalar plans to launch OraVerse at this year's American Dental Association (ADA) Annual Session being held in San Antonio, Texas from October 16-20, 2008. Novalar's sales force will focus on general and pediatric dentists for use in patients over six years of age.

Over 300 million cartridges of local dental anesthetic are sold each year in the U.S. alone. Although widely used, it frequently results in unnecessary and lingering soft tissue anesthesia and associated functional deficits. Novalar's market research with both patients and dentists has indicated strong interest in a product that will reduce the time to normal sensation and function following local dental anesthesia.

OraVerse's approval for use in adults and children is based on data from several clinical studies, including two Phase 3 studies in adults and adolescents age 12 and older and a Phase 2 pediatric study. The two Phase 3 studies were conducted in 18 centers across
'/>"/>

SOURCE Novalar Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
2. U.S. Navy Receives Funding for Further Development of Hemopure(R)
3. UCSF receives funding for building from California stem cell agency
4. USC receives nearly $27 million in funding for new stem cell research facility
5. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
6. Presbyterian Hospital of Plano Receives Prestigious Texas Award for Performance Excellence
7. Boston Medical Center/Boston University School of Medicine researcher receives award
8. Canadian Company Receives Final Tender Approval From Rwanda For Vital AIDS Drug
9. Quatro Composites Receives ISO 9001:2000 and AS9100:2004 Certification
10. Vascular Insights Receives FDA Clearance for Infusion Catheter
11. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding dresses, ... business offers a wide range of special occasion dresses, ... them to create multiple looks easily. , According to ... of chic wedding dresses has been prepared for many ... rates now. Dylan Queen can always create what ladies ...
(Date:11/22/2014)... November 22, 2014 Nocturia is ... the complaint that the individual has to wake ... The report “Nocturia – Pipeline Review, H2 2014” ... Nocturia, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication is ... states that, “While they give off the appearance of simplicity ... creating this powerful look.” , One of the first and ... kind of block matches your home environment and best fulfills ... main options are concrete and stone blocks. But do not ...
(Date:11/22/2014)... St. Petersburg, FL (PRWEB) November 22, 2014 ... Kitchen Innovations are pleased to announce that ... of the Thanksgiving #PayItForward contest. , Ms. Lombardo ... package from Kitchen Innovations. She wrote of how her ... beautiful, young daughters as a single mom. Despite medical ...
(Date:11/22/2014)... November 22, 2014 “Greenfield Naturals” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... the flavor of your water. , From pollution to ... important that everything is done to remove these chemicals, ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2
... Jerrold ... Connolly Medical Ltd. , ... (Vocus) January 29, 2010 -- Berkeley Heights – Jerrold S. Lozner, M.D., M.H.A., ... named as a “Top Doctor for Women’s Health” by Castle Connolly Medical, Ltd, in ...
... Pa. , Jan. 29 The Susan P. ... educate and inspire people of all ages to make healthy ... as President and CEO.  A talented non-profit leader, his goal ... expanding the delivery and distribution of health education services by ...
... , , Provides oral regime for hormone ... SPRING, Md. , Jan. 29 The U.S. ... with Femara (letrozole) to treat hormone positive and HER2-positive advanced ... indicated. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , HER2 ...
... respiratory weakness as a factor in the morbidity of ... that could improve long-term patient outcomes while reducing costs ... chair of research for the Department of Internal Medicine ... awarded a highly competitive, two-year, $480,000/year NIH Challenge Grant ...
... ... Following is the National Council on Disability,s monthly bulletin for December ... NCD,s award-winning Web site ( http://www.ncd.gov ), brings you the latest issues ... go to http://listserv.access.gpo.gov , click on "Online mailing list archives," select ...
... HANOVER TOWNSHIP, Pa. , Jan. 29 During a ... Secretary Everette James and Secretary of Education Gerald ... activity among middle school students. , "One-third of all Pennsylvania ... a lifetime of health problems," said James. "Schools like Hanover ...
Cached Medicine News:Health News:Summit Medical Group Physician Named 'Top Doctor for Women's Health' 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 3Health News:FDA Expands Use of Approved Breast Cancer Drug 2Health News:FDA Expands Use of Approved Breast Cancer Drug 3Health News:Kentucky research looks at respiratory weakness in ICU morbidity 2Health News:National Council on Disability Monthly Bulletin for January 2010 2Health News:National Council on Disability Monthly Bulletin for January 2010 3Health News:National Council on Disability Monthly Bulletin for January 2010 4Health News:National Council on Disability Monthly Bulletin for January 2010 5Health News:National Council on Disability Monthly Bulletin for January 2010 6Health News:National Council on Disability Monthly Bulletin for January 2010 7Health News:National Council on Disability Monthly Bulletin for January 2010 8Health News:National Council on Disability Monthly Bulletin for January 2010 9Health News:State Health, Education Leaders Applaud Luzerne County School for Boosting Physical Activity Among Students 2
(Date:11/21/2014)... MONTREAL , Nov. 21, 2014 /PRNewswire/ ... that the European Medicines Agency (EMA) has ... the company,s lead product candidate, for the ... is a rare, severely disabling genetic disease ... tissue swelling (flare-ups) and new abnormal bone ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... be Presented, PRINCETON, N.J., Sept. 4 ... nine clinical abstracts for ipilimumab,an investigational anti-CTLA-4 antibody, ... presentations at the 33rd Congress of the European ... 2008 in Stockholm.,Many of the following abstracts will ...
... for Targeted Therapies ... Benefits of Personalized Treatment HUNTINGTON BEACH, ... leader in molecular cancer diagnostics,today announced the launch of ... determine the gene expression levels of,the estrogen receptor (ER), ...
Cached Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Agendia Launches TargetPrint(R) for Breast Cancer Patients 2
... your camera upon arrival.,Our technician then makes note ... with a thorough customer quote. We respect that ... so well help you prioritize repairs. With customer ... , ISI uses only OEM or widely approved ...
... carefully inspects your equipment upon arrival. Our technician ... and provides you with a thorough customer quote. ... a tight budget so well help you prioritize ... repair begins., , ISI uses only OEM or ...
... Infinity™ AST single liquid stable reagent ... quantitative determination of AST in serum. ... only provides excellent stability and convenience ... against existing assays. The reagent is ...
... Konelab 30 is a fully automated, versatile ... analytical needs in mind. Konelab 30 is ... tests, specific proteins, therapeutic drugs, drugs of ... applications. Its flexibility also makes the analyzer ...
Medicine Products: